Studies Investigating Predictive Ability of Interim PET Imaging in HL
| Results | ||||
| Study | Patient population | Cycles completed before imaging | PET+ | PET− |
| Gallamini, 2007 (17) | 190 advanced-HL patients | 2 (ABVD) | 2-y PFS: 12.8% | 2-y PFS: 95.0% |
| Cerci, 2010 (18) | 115 advanced-HL patients | 2 (ABVD) | 3-y EFS: 53.4% | 3-y EFS: 90.5% |
| Barnes, 2011 (15) | 96 limited-HL patients | 2–4 (ABVD) | 4-y PFS: 87%* | 4-y PFS: 91%* |
| Le Roux, 2011 (13) | 90 patients with HL (45 limited, 45 advanced) | 4 (ABVD) | 2-y PFS: 16% | 2-y PFS: 95% |
| Straus, 2011 (49) | 99 limited-HL patients | 2 (doxorubicin, vinblastine, gemcitabine) | 2-y PFS: 54% | 2-y PFS: 88% |
| Kostakoglu, 2012 (20) | 88 limited-HL patients | 2 (doxorubicin, vinblastine, gemcitabine) | 2-y PFS: 54% (IHP), 46% (D5PS), 62% (CT) | 2-y PFS: 88% (IHP), 87% (D5PS), 91% (CT) |
| Markova, 2012 (14) | 69 advanced-HL patients | 4 (escalated BEACOPP) | 4-y PFS: 78% | 4-y PFS: 96% |
| Biggi, 2013 (6) | 260 advanced-HL patients | 2 (ABVD) | 3-y FFS: 28% | 3-y FFS: 95% |
| Filippi, 2013 (16) | 80 limited-HL patients | 2 (ABVD) | 3-y PFS: 100%* | 3-y PFS: 97%* |
| Gallamini, 2014 (7) | 207 advanced-HL patients | 2 (ABVD) | 3-y PFS: 28% | 3-y PFS: 95% |
| Hutchings, 2014 (12) | 126 HL patients (68 limited, 58 advanced) | 1–2 (ABVD) | 2-y PFS: 38.5% (PET-1), 23.1% (PET-2) | 2-y PFS: 98.3% (PET-1), 90.2% (PET-2) |
| Oki, 2014 (19) | 229 HL patients (138 limited, 91 advanced) | 2–3 (ABVD) | 3-y PFS: 76.9% (limited), 20.0% (limited, bulky), 44.4% (advanced) | 3-y PFS: 95.9% (limited), 83.3% (limited, bulky), 71.0% (advanced) |
| Rossi, 2014 (50) | 59 HL patients (22 limited, 37 advanced) | 2 (anthracycline-based chemotherapy) | 4-y PFS: 45% | 4-y PFS: 81% |
↵* Nonsignificant.
IHP = International Harmonization Project criteria; FFS = failure-free survival.